Market Update

2H 2018 Life Sciences Software Market Update

Madison Park Group (MPG) actively tracks the life sciences software landscape and has been instrumental in strategic deals across the drug development & commercial spectrum.

Through MPG’s time in the space, we’ve noticed a number of trends and developments:

  • Continued increase in pharma R&D spend coupled with a need to optimize trial costs and ROI provides ample market opportunity for clinical trial software vendors
  • Convergence of software, data and analytical tools to optimize life sciences decision-making, especially through the use of Real World Evidence
  • Pre-clinical vendors continue to capitalize on Standard for the Exchange of Nonclinical Data (SEND) regulations through both software and outsourced services

Practice Leaders

Rohan Khanna
Managing Director

Jonathan Adler
Managing Director

Get in touch with us

Contact Us

  • Hidden
  • This field is for validation purposes and should be left unchanged.